- Home
- RFL vs BRNS Comparison
RFL vs BRNS Comparison
Compare RFL & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- BRNS
- Stock Information
- Founded
- RFL 2017
- BRNS 2016
- Country
- RFL United States
- BRNS United Kingdom
- Employees
- RFL N/A
- BRNS N/A
- Industry
- RFL Real Estate
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- BRNS Health Care
- Exchange
- RFL Nasdaq
- BRNS Nasdaq
- Market Cap
- RFL 67.7M
- BRNS 42.8M
- IPO Year
- RFL N/A
- BRNS 2021
- Fundamental
- Price
- RFL $2.05
- BRNS $1.48
- Analyst Decision
- RFL
- BRNS Strong Buy
- Analyst Count
- RFL 0
- BRNS 1
- Target Price
- RFL N/A
- BRNS $3.00
- AVG Volume (30 Days)
- RFL 238.1K
- BRNS 3.6M
- Earning Date
- RFL 06-11-2025
- BRNS 08-07-2025
- Dividend Yield
- RFL N/A
- BRNS N/A
- EPS Growth
- RFL N/A
- BRNS N/A
- EPS
- RFL N/A
- BRNS N/A
- Revenue
- RFL $732,000.00
- BRNS $14,969,000.00
- Revenue This Year
- RFL N/A
- BRNS N/A
- Revenue Next Year
- RFL N/A
- BRNS N/A
- P/E Ratio
- RFL N/A
- BRNS N/A
- Revenue Growth
- RFL 35.56
- BRNS 4381.74
- 52 Week Low
- RFL $1.28
- BRNS $0.64
- 52 Week High
- RFL $3.19
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- RFL 59.74
- BRNS 82.28
- Support Level
- RFL $2.09
- BRNS $0.96
- Resistance Level
- RFL $2.32
- BRNS $2.92
- Average True Range (ATR)
- RFL 0.19
- BRNS 0.23
- MACD
- RFL 0.03
- BRNS 0.07
- Stochastic Oscillator
- RFL 57.23
- BRNS 32.92
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.